In the article "Disabling CCR5 Could Be Key to a Cure—but at What Cost" they make a case against CCR5 inhibition. With any method that involves eliminating or complete blockage of CCR5 they may have a point. In an individual exhibiting CCR5, eliminating it results in the immune system using secondary receptors with less binding affinity.

Their citing of the white paper "Deviations from Hardy Weinberg Equilibrium at CCR5-Δ32 in Large Sequencing Data Sets?" is a bit off since the contributing data is not trustworthy and states that at the top of the paper.
https://www.biorxiv.org/content/10.1101/768390v2

But then we come to leronlimab. Leronlimab establishes only a partial blockade of the CCR5 receptor and still allows immune system function. That the developers of leronlimab chose this particular molecular structure was quite fortuitous.